TSCAN THERAPEUTICS, INC. Operating Expenses
TSCAN THERAPEUTICS, INC. (TCRX) reported Operating Expenses of $31.54 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-12
- TSCAN THERAPEUTICS, INC. operating expenses for the quarter ending 2026-06-30 was $31.54M, a 24.41% decline year-over-year.
- TSCAN THERAPEUTICS, INC. operating expenses for the quarter ending 2026-03-31 was $30.12M, a 21.60% decline year-over-year.
- TSCAN THERAPEUTICS, INC. operating expenses for the quarter ending 2025-12-31 was $26.43M, a 29.30% decline year-over-year.
- TSCAN THERAPEUTICS, INC. operating expenses for the quarter ending 2025-09-30 was $39.56M, a 17.50% increase year-over-year.
- TSCAN THERAPEUTICS, INC. operating expenses for fiscal 2025 was $146.14M, a 6.18% increase from fiscal 2024.
- TSCAN THERAPEUTICS, INC. operating expenses for fiscal 2024 was $137.64M, a 20.20% increase from fiscal 2023.
- TSCAN THERAPEUTICS, INC. operating expenses for fiscal 2023 was $114.51M, a 42.83% increase from fiscal 2022.
- TSCAN THERAPEUTICS, INC. operating expenses for fiscal 2022 was $80.17M, a 36.39% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $31.54M 10-Q · filed 2026-08-12 | $61.66M 10-Q · filed 2026-08-12 | $88.09M derived: sum of 3 quarters · filed 2026-08-12 | $127.65M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $30.12M 10-Q · filed 2026-05-06 | $56.55M derived: sum of 2 quarters · filed 2026-05-06 | $96.11M derived: sum of 3 quarters · filed 2026-05-06 | $137.84M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $26.43M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $65.99M derived: sum of 2 quarters · filed 2026-03-04 | $107.72M derived: sum of 3 quarters · filed 2026-08-12 | $146.14M 10-K · filed 2026-03-04 |
| 2025-09-30 | $39.56M 10-Q · filed 2025-11-12 | $81.29M derived: sum of 2 quarters · filed 2026-08-12 | $119.71M 10-Q · filed 2025-11-12 | $157.09M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $41.73M 10-Q · filed 2026-08-12 | $80.15M 10-Q · filed 2026-08-12 | $117.53M derived: sum of 3 quarters · filed 2026-08-12 | $151.20M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $38.42M 10-Q · filed 2026-05-06 | $75.80M derived: sum of 2 quarters · filed 2026-05-06 | $109.47M derived: sum of 3 quarters · filed 2026-05-06 | $144.12M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $37.38M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $71.05M derived: sum of 2 quarters · filed 2026-03-04 | $105.70M derived: sum of 3 quarters · filed 2026-03-04 | $137.64M 10-K · filed 2026-03-04 |
| 2024-09-30 | $33.67M 10-Q · filed 2025-11-12 | $68.32M derived: sum of 2 quarters · filed 2025-11-12 | $100.26M 10-Q · filed 2025-11-12 | $128.83M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $34.65M 10-Q · filed 2025-08-12 | $66.59M 10-Q · filed 2025-08-12 | $95.16M derived: sum of 3 quarters · filed 2025-08-12 | $123.79M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $31.94M 10-Q · filed 2025-05-06 | $60.51M derived: sum of 2 quarters · filed 2025-05-06 | $89.14M derived: sum of 3 quarters · filed 2025-05-06 | $116.90M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | $28.57M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | $57.20M derived: sum of 2 quarters · filed 2025-03-05 | $84.96M derived: sum of 3 quarters · filed 2025-03-05 | $114.51M 10-K · filed 2025-03-05 |
| 2023-09-30 | $28.64M 10-Q · filed 2024-11-12 | $56.39M derived: sum of 2 quarters · filed 2024-11-12 | $85.94M 10-Q · filed 2024-11-12 | $107.68M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $27.76M 10-Q · filed 2024-08-12 | $57.30M 10-Q · filed 2024-08-12 | $79.05M derived: sum of 3 quarters · filed 2024-08-12 | $98.99M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $29.55M 10-Q · filed 2024-05-13 | $51.29M derived: sum of 2 quarters · filed 2024-05-13 | $71.23M derived: sum of 3 quarters · filed 2024-05-13 | $90.53M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $21.74M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | $41.69M derived: sum of 2 quarters · filed 2024-03-06 | $60.99M derived: sum of 3 quarters · filed 2024-03-06 | $80.17M 10-K · filed 2024-03-06 |
| 2022-09-30 | $19.94M 10-Q · filed 2023-11-09 | $39.24M derived: sum of 2 quarters · filed 2023-11-09 | $58.43M 10-Q · filed 2023-11-09 | $75.48M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $19.30M 10-Q · filed 2023-08-10 | $38.49M 10-Q · filed 2023-08-10 | $55.54M derived: sum of 3 quarters · filed 2023-08-10 | $73.80M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $19.18M 10-Q · filed 2023-05-10 | $36.24M derived: sum of 2 quarters · filed 2023-05-10 | $54.49M derived: sum of 3 quarters · filed 2023-05-10 | $68.02M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $17.06M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | $35.31M derived: sum of 2 quarters · filed 2023-03-08 | $48.84M derived: sum of 3 quarters · filed 2023-03-08 | $58.78M 10-K · filed 2023-03-08 |
| 2021-09-30 | $18.25M 10-Q · filed 2022-11-09 | $31.78M derived: sum of 2 quarters · filed 2022-11-09 | $41.73M 10-Q · filed 2022-11-09 | $50.33M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $13.53M 10-Q · filed 2022-08-10 | $23.47M 10-Q · filed 2022-08-10 | $32.08M derived: sum of 3 quarters · filed 2022-08-10 | $39.54M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $9.95M 10-Q · filed 2022-05-12 | $18.55M derived: sum of 2 quarters · filed 2022-05-12 | $26.01M derived: sum of 3 quarters · filed 2022-05-12 | $31.63M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $8.61M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-09 | $16.07M derived: sum of 2 quarters · filed 2022-03-09 | $21.68M derived: sum of 3 quarters · filed 2022-03-09 | $27.32M 10-K · filed 2022-03-09 |
| 2020-09-30 | $7.46M 10-Q · filed 2021-11-10 | $13.08M derived: sum of 2 quarters · filed 2021-11-10 | $18.71M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $5.62M 10-Q · filed 2021-08-19 | $11.25M 10-Q · filed 2021-08-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B |